NEW YORK, Nov. 18 Reportlinker.com announces that a new market research report is available in its catalogue.
Anticoagulants - A Global Market Review
Advertisement
http://www.reportlinker.com/p0164225/Anticoagulants---A-Global-Market-Review.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire
The world anticoagulants market is driven by patent expiries, development of novel therapeutics, and rapidly aging population. With just two therapy classes - vitamin K antagonist and heparin injectables, dominating the market, there exist enormous opportunities and interest in developing advanced, patient friendly anticoagulants. Favorable demographic patterns, like the rapidly aging world population is expected to drive demand patterns, given the tendency of aging individuals to develop various venous and arterial complications.
Advertisement
The unmet medical needs of available anticoagulants offer ample scope for development in the world anticoagulants market. Continuous research and development is expected to result in novel therapies with superior therapeutic efficiency, and minimum side effects. These advanced therapeutics offer promising market prospects. Identification of new indications for existing, and emerging therapies is expected to help open up brighter prospects for further growth. Factor Xa inhibitors (oral and injectable) and direct thrombin inhibitors (oral and injectable) are among the new class of thrombin antagonists that are being evaluated for both existing as well as newer indications.
These and other market data and trends are presented in "Anticoagulants: A Global Market Review" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.
ANTICOAGULANTS BMR-1025
CONTENTS
1. METHODOLOGY 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Quantitative Techniques & Reporting Level 3
2. GLOBAL MARKET OVERVIEW AND OUTLOOK 4
3. MARKET SCENARIO 4
A Snapshot of Available Therapies 5
An Insight into Currently Available Antithrombotic Drugs 5
Weaknesses of Available Therapies 6
Forces Driving the Market 6
Oral Anticoagulants Market 6
Injectable Anticoagulants Market 7
Heparin Market 7
LMWH Market 7
4. MARKET DYNAMICS 8
Drug Advancements Drive Anticoagulant Market 8
Niche Markets - The New Target for Drug Makers 8
An Opportunity to Grow Further 8
Geriatric Patients - At High Risk of Blood Clots 9
Improved Anticoagulant Agents for Children Group 9
Growing Demand for Self-Testing 9
LMWHs Eases Outpatient Management 9
Concern Over Underutilization of Warfarin 10
Anticoagulants to Lose UA/AMI Markets to Antiplatelets 10
Influx of New Drugs Invigorates the Market 10
Novel Heparins Enhances Market Potential 11
Anticoagulant Therapy During Pregnancy Improves Outcomes 11
New Therapies: Need of the Hour 11
Anticoagulant Therapy in IPF: Reduces Mortality Risk 11
Failure of Exanta 12
5. PRODUCT FACTS 12
Anticoagulants 12
Indications for Anticoagulant Use 12
List of Approved Anticoagulants for Pulmonary Embolism 13
List of Approved Anticoagulants for Orthopedic Surgery 13
List of Approved Anticoagulants for General Surgery 13
List of Approved Anticoagulants for Atrial Fibrillation 14
List of Approved Anticoagulants for Unstable Angina 14
List of Approved Anticoagulants for Non-ST Segment Elevation
Myocardial Infraction 14
List of Approved Anticoagulants for Angioplasty Procedures 15
List of Approved Anticoagulants for HIT Type II 15
6. DRUG DEVELOPMENT PIPELINE 15
Select Anticoagulants Under Pipeline 15
Idraparinux - Sanofi-Aventis 16
0673 - Sanofi-Aventis 16
BIBR1048MS - Boehringer Ingelheim 17
7. CORPORATE DEVELOPMENTS 17
PAION Acquires CeNes Pharmaceuticals 17
PAION Announces Acquisition of Global Rights to Trigen's
flovagatran 17
Biological E Collaborates with Choncept and Heparinex 17
Bayer's Market Expansion 18
B. Braun Recalls Heparin Sodium Based Injection Solutions 18
Baxter Recalls Heparin Sodium Vials 18
Boehringer Receives EU Approval for Pradaxa 18
Sanofi-Aventis Receives Approval for Clexane® in Japan 19
ParagonDx Receives US FDA Approval for its Rapid Genotyping Assay 19
Lannett Obtains US FDA Approval for Dipyridamole Tablets 19
Celgene Acquires Pharmion 19
BMS Collaborates with Pfizer 20
Medicines Company Reacquires European Rights for Angiox 20
HemoSense and LabCorp Sign Agreement for Supply of INRatio System 21
Sanofi-Aventis Acquires Rights for Panaldine from Daiichi 21
Alchemia Inks Marketing Alliance with Dr Reddy's for Heparin 21
Inverness Announces Acquisition of HemoSense 22
ev3, FoxHollow Complete Merger 22
Osmetech Signs Licensing Agreement with Marshfield Clinic 22
Mitsubishi and Tanabe Agree to Merge 23
Artisan and A-Bio Form Alliance 23
Kimball Introduces New Pharmacogenetic Test 23
Roche Launches an Improved Point-of- Care Anticoagulation
Monitoring System 24
Danish Agency Grants Approval for Anticoagulant Clinical Trials 24
EMEA Approves ARIXTRA® of GlaxoSmithKline 24
FDA Approves ANDAs of PLIVA 24
FDA Approves ARIXTRA Injection of GSK 24
Japanese Ministry Approves Arixtra of GSK 25
Eisai Obtains FDA Approval for Fragmin 25
Sanofi-Aventis' Lovenox® Obtains FDA Approval for Acute
Cardiac Care 25
8. MAJOR PLAYERS 26
AstraZeneca PLC (UK) 26
Bristol-Myers Squibb Company (USA) 26
Celgene Corporation (USA) 26
GlaxoSmithKline plc (UK) 26
Mitsubishi Tanabe Pharma Corporation (Japan) 27
Pfizer Inc. (USA) 27
Sanofi-Aventis (France) 27
9. MARKET ANALYTICS 28
10. THE UNITED STATES 34
Atrial Fibrillation - A Key Risk Factor 34
Regulatory Route to the US Market 34
Phase I Clinical Trials 34
Phase II Clinical Trials 34
Phase III Clinical Trials 34
Price Controls 35
US Anticoagulants Market 35
US Heparin Market 35
Hinging on Market Opportunities 36
Generics - Threatening Branded Anticoagulants 36
List of Patent Protected Anticoagulants in the US 37
Ignorance - A Major Hindrance 37
Future Challenges and Growth Drivers 37
US Emerging Anticoagulant Market 38
US Emerging Anticoagulants Market: Products in the Pipeline 38
11. JAPAN 40
Anticoagulants Market in Japan 40
Rising Incidence of Pulmonary Thromboembolism 40
12. EUROPE 42
a. France 45
b. Germany 46
c. Italy 47
d. The United Kingdom 48
e. Spain 49
f. Rest of Europe 50
13. REST OF WORLD 51
Table 1: Global Anticoagulants Market by Region for the Period
2007-2015 (Sales in US$ Million)
Table 2: Percentage Breakdown of Global Anticoagulants Market
by Region for the Years 2008 & 2012
Table 3: Global Oral Anticoagulants Market by Region for the
Period 2007-2015 (Sales in US$ Million)
Table 4: Percentage Breakdown of Global Oral Anticoagulants
Market by Region for the Years 2008 & 2012
Table 5: Global Injectable Anticoagulants Market by Region for
the Period 2007-2015 (Sales in US$ Million)
Table 6: Percentage Breakdown of Global Injectable
Anticoagulants Market by Region for the Years 2008 & 2012
Table 7: Global Injectable Anticoagulants Market by Segment
for the Period 2007-2015 (Sales in US$ Million)
Table 8: Percentage Breakdown of Global Injectable
Anticoagulants Market by Segment for the Years 2008 & 2012
Table 9: Global Unfractionated Heparin Market by Region for
the Period 2007-2015 (Sales in US$ Million)
Table 10: Percentage Breakdown of Global Unfractionated
Heparin Market by Region for the Years 2008 & 2012
Table 11: Global Low Molecular Weight Heparin Market by Region
for the Period 2007-2015 (Sales in US$ Million)
Table 12: Percentage Breakdown of Global Low Molecular Weight
Heparin Market by Region for the Years 2008 & 2012
Table 13: Anticoagulants Market by Segment in the US:
2007-2015 (Sales in US$ Million)
Table 14: Percentage Breakdown of Anticoagulants Market by
Segment in the US for the Years 2008 & 2012
Table 15: Anticoagulants Market by Segment in Japan: 2007-2015
(Sales in US$ Million)
Table 16: Percentage Breakdown of Anticoagulants Market by
Segment in Japan for the Years 2008 & 2012
Table 17: Anticoagulants Market by Region in Europe: 2007-2015
(Sales in US$ Million)
Table 18: Percentage Breakdown of Anticoagulants Market by
Region in Europe for the Years 2008 & 2012
Table 19: Anticoagulants Market by Segment in Europe:
2007-2015 (Sales in US$ Million)
Table 20: Percentage Breakdown of Anticoagulants Market by
Segment in Europe for the Years 2008 & 2012
Table 21: Anticoagulants Market by Segment in France:
2007-2015 (Sales in US$ Million)
Table 22: Percentage Breakdown of Anticoagulants Market by
Segment in France for the Years 2008 & 2012
Table 23: Anticoagulants Market by Segment in Germany:
2007-2015 (Sales in US$ Million)
Table 24: Percentage Breakdown of Anticoagulants Market by
Segment in Germany for the Years 2008 & 2012
Table 25: Anticoagulants Market by Segment in Italy: 2007-2015
(Sales in US$ Million)
Table 26: Percentage Breakdown of Anticoagulants Market by
Segment in Italy for the Years 2008 & 2012
Table 27: Anticoagulants Market by Segment in the UK:
2007-2015 (Sales in US$ Million)
Table 28: Percentage Breakdown of Anticoagulants Market by
Segment in the UK for the Years 2008 & 2012
Table 29: Anticoagulants Market by Segment in Spain: 2007-2015
(Sales in US$ Million)
Table 30: Percentage Breakdown of Anticoagulants Market by
Segment in Spain for the Years 2008 & 2012
Table 31: Anticoagulants Market by Segment in the Rest of
Europe: 2007-2015 (Sales in US$ Million)
Table 32: Percentage Breakdown of Anticoagulants Market by
Segment in the Rest of Europe for the Years 2008 & 2012
Table 33: Anticoagulants Market by Segment in Rest of World:
2007-2015 (Sales in US$ Million)
Table 34: Percentage Breakdown of Anticoagulants Market by
Segment in Rest of World for the Years 2008 & 2012
COMPANIES PROFILED
To order this report:
Anticoagulants - A Global Market Review
http://www.reportlinker.com/p0164225/Anticoagulants---A-Global-Market-Review.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire
More market research reports here!
Contact: Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
